Results 171 to 180 of about 66,897 (261)

Female Sex as a Major Risk Factor for Dabigatran‐Induced Esophagitis in Atrial Fibrillation Ablation

open access: yesJournal of Arrhythmia, Volume 42, Issue 2, April 2026.
Dabigatran‐induced esophagitis occurred in 18.7% of patients undergoing atrial fibrillation ablation. Female sex was identified as an independent predictor of this complication, highlighting the need for careful periprocedural management and preventive strategies in women.
Daiki Saito   +16 more
wiley   +1 more source

Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials. [PDF]

open access: yesEur Heart J Cardiovasc Pharmacother
Cannatà A   +9 more
europepmc   +1 more source

Assessment of the impact of furosemide use on outcomes in patients with intra-abdominal hypertension: a retrospective cohort study from the MIMIC-IV database. [PDF]

open access: yesBMC Gastroenterol
Wang J   +15 more
europepmc   +1 more source

Case of Gastric Signet Ring Cell Carcinoma With Pulmonary Lymphangitic Carcinomatosis as the Initial Manifestation Diagnosed by Computed Tomography‐Guided Percutaneous Lung Biopsy

open access: yesRespirology Case Reports, Volume 14, Issue 4, April 2026.
We report a case of gastric signet ring cell carcinoma with pulmonary lymphangitic carcinomatosis as the initial manifestation without gastrointestinal symptoms confirmed by CT‐guided percutaneous lung biopsy, with the aim of providing insights into diagnostic methods and differential diagnosis of similar cases.
Ping Li   +3 more
wiley   +1 more source

Clinical Parameters Associated with Achieving Negative Fluid Balance in Critically Ill Patients: A Retrospective Cohort Study. [PDF]

open access: yesJ Clin Med
Stavi D   +10 more
europepmc   +1 more source

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 955-966, April 2026.
In the phase I/IIa GOING trial, an add‐on strategy with regorafenib followed by nivolumab showed a manageable safety profile and meaningful clinical activity in second‐line hepatocellular carcinoma, with a median overall survival of 25 months and 45% three‐year survival in sorafenib‐experienced patients.
Marco Sanduzzi‐Zamparelli   +24 more
wiley   +1 more source

Consciousness Disturbances Reported With Clindamycin Versus Cefazolin in Surgical Patients: A Global Pharmacovigilance Analysis Using VigiBase

open access: yesClinical and Translational Science, Volume 19, Issue 4, April 2026.
ABSTRACT Clindamycin is a common β‐lactam substitute for surgical prophylaxis. Whether peri‐operative disturbances in consciousness are disproportionately reported with clindamycin in global pharmacovigilance data remains unclear. Using WHO VigiBase (up to January 27, 2025), we performed a de‐duplicated case/non‐case disproportionality analysis of ...
Kazuki Nishida   +8 more
wiley   +1 more source

Continuous Versus Intermittent Loop Diuretics Step-by-Step Protocol in Acute Heart Failure (DIUR-AHF): A Propensity-Matched Analysis. [PDF]

open access: yesJ Am Heart Assoc
Ruocco G   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy